India · Delayed Price · Currency is INR Ajanta Pharma Statistics
Total Valuation
Ajanta Pharma has a market cap or net worth of INR 432.76 billion. The enterprise value is 428.72 billion.
| Market Cap | 432.76B |
| Enterprise Value | 428.72B |
Important Dates
The last earnings date was Thursday, July 30, 2026.
| Earnings Date | Jul 30, 2026 |
| Ex-Dividend Date | Aug 5, 2026 |
Share Statistics
Ajanta Pharma has 124.89 million shares outstanding. The number of shares has increased by 0.02% in one year.
| Current Share Class | 124.89M |
| Shares Outstanding | 124.89M |
| Shares Change (YoY) | +0.02% |
| Shares Change (QoQ) | +0.08% |
| Owned by Insiders (%) | 42.21% |
| Owned by Institutions (%) | 22.73% |
| Float | 42.00M |
Valuation Ratios
The trailing PE ratio is 38.16 and the forward PE ratio is 33.86. Ajanta Pharma's PEG ratio is 2.03.
| PE Ratio | 38.16 |
| Forward PE | 33.86 |
| PS Ratio | 7.49 |
| PB Ratio | 9.56 |
| P/TBV Ratio | 9.65 |
| P/FCF Ratio | 263.83 |
| P/OCF Ratio | 81.78 |
| PEG Ratio | 2.03 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 27.05, with an EV/FCF ratio of 261.36.
| EV / Earnings | 37.78 |
| EV / Sales | 7.42 |
| EV / EBITDA | 27.05 |
| EV / EBIT | 30.64 |
| EV / FCF | 261.36 |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.06 |
| Debt / EBITDA | 0.16 |
| Debt / FCF | 1.59 |
| Interest Coverage | 99.73 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 25.79% |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | 5.41% |
| Revenue Per Employee | 6.00M |
| Profits Per Employee | 1.18M |
| Employee Count | 9,628 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Ajanta Pharma has paid 3.58 billion in taxes.
| Income Tax | 3.58B |
| Effective Tax Rate | 24.00% |
Stock Price Statistics
The stock price has increased by +23.91% in the last 52 weeks. The beta is 0.21, so Ajanta Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.21 |
| 52-Week Price Change | +23.91% |
| 50-Day Moving Average | 3,230.54 |
| 200-Day Moving Average | 2,877.43 |
| Relative Strength Index (RSI) | 58.72 |
| Average Volume (20 Days) | 115,009 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Ajanta Pharma had revenue of INR 57.76 billion and earned 11.35 billion in profits. Earnings per share was 90.80.
| Revenue | 57.76B |
| Gross Profit | 45.40B |
| Operating Income | 13.99B |
| Pretax Income | 14.93B |
| Net Income | 11.35B |
| EBITDA | 15.85B |
| EBIT | 13.99B |
| Earnings Per Share (EPS) | 90.80 |
Balance Sheet
The company has 6.65 billion in cash and 2.60 billion in debt, with a net cash position of 4.04 billion or 32.39 per share.
| Cash & Cash Equivalents | 6.65B |
| Total Debt | 2.60B |
| Net Cash | 4.04B |
| Net Cash Per Share | 32.39 |
| Equity (Book Value) | 45.27B |
| Book Value Per Share | 362.40 |
| Working Capital | n/a |
Cash Flow
In the last 12 months, operating cash flow was 5.29 billion and capital expenditures -3.65 billion, giving a free cash flow of 1.64 billion.
| Operating Cash Flow | 5.29B |
| Capital Expenditures | -3.65B |
| Depreciation & Amortization | 1.85B |
| Net Borrowing | 1.98B |
| Free Cash Flow | 1.64B |
| FCF Per Share | 13.13 |
Margins
Gross margin is 78.61%, with operating and profit margins of 24.22% and 19.65%.
| Gross Margin | 78.61% |
| Operating Margin | 24.22% |
| Pretax Margin | 25.85% |
| Profit Margin | 19.65% |
| EBITDA Margin | 27.43% |
| EBIT Margin | 24.22% |
| FCF Margin | 3.01% |
Dividends & Yields
This stock pays an annual dividend of 28.00, which amounts to a dividend yield of 0.81%.
| Dividend Per Share | 28.00 |
| Dividend Yield | 0.81% |
| Dividend Growth (YoY) | -48.15% |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.02% |
| Shareholder Yield | 0.79% |
| Earnings Yield | 2.62% |
| FCF Yield | 0.38% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Ajanta Pharma is 3,504.36, which is -1.26% lower than the current price. The consensus rating is "Buy".
| Price Target | 3,504.36 |
| Price Target Difference | -1.26% |
| Analyst Consensus | Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (3Y) | 12.68% |
| EPS Growth Forecast (3Y) | 13.89% |
Stock Splits
The last stock split was on June 22, 2022. It was a forward split with a ratio of 1.5.
| Last Split Date | Jun 22, 2022 |
| Split Type | Forward |
| Split Ratio | 1.5 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |